Skip to Content
Proven Success to

Give you an edge

Professionally serviced


Products marketed in


Growing team of


Regulatory and Former FDA experts
Life Sciences Products

Our Expertise

By partnering with us, you gain a strategic advantage in a rapidly evolving biotech landscape. We stay at the forefront of global regulatory updates, industry trends, and technological advancements, ensuring that you benefit from the latest insights and best practices. Our commitment to excellence, unwavering client focus, and dedication to advancing patient care make us your trusted partner in transforming the life sciences industry.

Our Difference

The Biologics Consulting difference is the world-class combination of expertise we have under one roof.

World-renowned scientists and physicians

Full scope of FDA regulatory support needs

Turning raw data into stories that resonate

Building global partnerships for regulatory success

More Than Just Consultants

Our Team

Our consultants are here to help you navigate the regulatory process and provide you with the best strategy for success.


News and Insights

September 21, 2023

Biologics Consulting Appoints Dr. Margaret K. Vernon As Its New Chief Executive Officer

Biologics Consulting Group, Inc. is pleased to announce the appointment of Dr. Margaret K. Vernon as Chief Executive Officer, effective September 18, 2023.

Read More
September 15, 2023  •  Webinar


Over the past several years, novel cell and gene therapy (CGT) products have rapidly progressed through the clinic, and several have gained regulatory approval. Advances in both cell and molecular biology as well as immunology and more efficient manufacturing paradigms have led to an explosion in new CGT products.

Gone are the days of relatively straightforward plasmid DNA and stem cell therapies. Today, new product paradigms including CAR-Ts, novel viral vectors, microbiome-derived bacterial products, phage therapies and mRNA therapies constantly provide new challenges to product developers.

What are some of the scientific, quality, and regulatory hurdles developers face with novel CGT products and how can biotech work most effectively with regulators to get these promising products into patients? Our panel will discuss some of the CMC and nonclinical challenges commonly faced with novel CGT products and how we might overcome them to bring these complex, but promising therapies to the clinic.
Listen in to Mike Grace, David Pepperl, Diana Colleluori, Robert Kutner, and Chris Scull as they discuss the challenges and some solutions.

Read More

Contact Us

Select one
Would you like to receive periodic informational and educational content on the latest research, developments and regulations from Biologics Consulting?*(Required)